ABSTRACT
Nascent transcription assays, such as global run-on sequencing (GRO-seq) and precision run-on sequencing (PRO-seq), have uncovered a myriad of unstable RNAs being actively produced from numerous sites genome-wide. These transcripts provide a more complete and immediate picture of the impact of regulatory events. Transcription factors recruit RNA polymerase II, effectively initiating the process of transcription; repressors inhibit polymerase recruitment. Efficiency of recruitment is dictated by sequence elements in and around the RNA polymerase loading zone. A combination of sequence elements and RNA binding proteins subsequently influence the ultimate stability of the resulting transcript. Some of these transcripts are capable of providing feedback on the process, influencing subsequent transcription. By monitoring RNA polymerase activity, nascent assays provide insights into every step of the regulated process of transcription.
Subject(s)
RNA/genetics , Transcription, Genetic/genetics , Animals , Enhancer Elements, Genetic/genetics , Humans , RNA Polymerase II/genetics , RNA Polymerase II/metabolism , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolismABSTRACT
CHD7, an ATP-dependent chromatin remodeler, is disrupted in CHARGE syndrome, an autosomal dominant disorder characterized by variably penetrant abnormalities in craniofacial, cardiac, and nervous system tissues. The inner ear is uniquely sensitive to CHD7 levels and is the most commonly affected organ in individuals with CHARGE. Interestingly, upregulation or downregulation of retinoic acid (RA) signaling during embryogenesis also leads to developmental defects similar to those in CHARGE syndrome, suggesting that CHD7 and RA may have common target genes or signaling pathways. Here, we tested three separate potential mechanisms for CHD7 and RA interaction: (a) direct binding of CHD7 with RA receptors, (b) regulation of CHD7 levels by RA, and (c) CHD7 binding and regulation of RA-related genes. We show that CHD7 directly regulates expression of Aldh1a3, the gene encoding the RA synthetic enzyme ALDH1A3 and that loss of Aldh1a3 partially rescues Chd7 mutant mouse inner ear defects. Together, these studies indicate that ALDH1A3 acts with CHD7 in a common genetic pathway to regulate inner ear development, providing insights into how CHD7 and RA regulate gene expression and morphogenesis in the developing embryo.
Subject(s)
Aldehyde Oxidoreductases/metabolism , CHARGE Syndrome/genetics , DNA Helicases/deficiency , DNA-Binding Proteins/deficiency , Gene Expression Regulation, Developmental , Retinal Dehydrogenase/metabolism , Tretinoin/metabolism , Aldehyde Oxidoreductases/genetics , Animals , CHARGE Syndrome/pathology , Cell Line, Tumor , DNA Helicases/genetics , DNA-Binding Proteins/genetics , Disease Models, Animal , Ear, Inner/embryology , Embryo, Mammalian , Female , Gene Expression Profiling , Gene Knockdown Techniques , HEK293 Cells , Humans , Male , Mice , Mice, Transgenic , Organogenesis/genetics , RNA, Small Interfering/metabolism , Retinal Dehydrogenase/geneticsABSTRACT
Histone deacetylase inhibitors (HDACIs) are known to alter gene expression by both up- and down-regulation of protein-coding genes in normal and cancer cells. However, the exact regulatory mechanisms of action remain uncharacterized. Here we investigated genome wide dose-dependent epigenetic and transcriptome changes in response to HDACI largazole in a transformed and a non-transformed cell line. Exposure to low nanomolar largazole concentrations (Subject(s)
Depsipeptides/pharmacology
, Enhancer Elements, Genetic
, Histone Code/drug effects
, Histone Deacetylase Inhibitors/pharmacology
, Thiazoles/pharmacology
, Acetylation
, Cell Line
, Cell Line, Transformed
, Cytostatic Agents/pharmacology
, Dose-Response Relationship, Drug
, Enhancer Elements, Genetic/drug effects
, Genome
, Histone Deacetylases/physiology
, Histones/metabolism
, Oncogenes
, Promoter Regions, Genetic
, RNA Polymerase II/metabolism
, RNA, Messenger/metabolism
ABSTRACT
Recent studies have demonstrated that MyoD initiates a feed-forward regulation of skeletal muscle gene expression, predicting that MyoD binds directly to many genes expressed during differentiation. We have used chromatin immunoprecipitation and high-throughput sequencing to identify genome-wide binding of MyoD in several skeletal muscle cell types. As anticipated, MyoD preferentially binds to a VCASCTG sequence that resembles the in vitro-selected site for a MyoD:E-protein heterodimer, and MyoD binding increases during differentiation at many of the regulatory regions of genes expressed in skeletal muscle. Unanticipated findings were that MyoD was constitutively bound to thousands of additional sites in both myoblasts and myotubes, and that the genome-wide binding of MyoD was associated with regional histone acetylation. Therefore, in addition to regulating muscle gene expression, MyoD binds genome wide and has the ability to broadly alter the epigenome in myoblasts and myotubes.